Your browser doesn't support javascript.
loading
Neutralizing Antibody Responses in COVID-19 Convalescent Sera
William T Lee; Roxanne C Girardin; Alan P Dupuis II; Karen E Kulas; Anne F Payne; Susan J Wong; Suzanne Arinsburg; Freddy T Nguyen; Damodara Rao Mendu; Adolfo Firpo-Betancourt; Jeffrey Jhang; Ania Wajnberg; Florian Krammer; Carlos Cordon-Cardo; Sherlita Amler; Marisa A Montecalvo; Brad Hutton; Jill Taylor; Kathleen A McDonough.
Affiliation
  • William T Lee; Wadsworth Center/New York State Department of Health
  • Roxanne C Girardin; Wadsworth Center/New York State Department of Health.
  • Alan P Dupuis II; Wadsworth Center/New York State Department of Health
  • Karen E Kulas; Wadsworth Center/New York State Department of Health
  • Anne F Payne; Wadsworth Center/New York State Department of Health
  • Susan J Wong; Wadsworth Center/New York State Department of Health
  • Suzanne Arinsburg; Icahn School of Medicine at Mount Sinai
  • Freddy T Nguyen; Icahn School of Medicine at Mount Sinai
  • Damodara Rao Mendu; Icahn School of Medicine at Mount Sinai
  • Adolfo Firpo-Betancourt; Icahn School of Medicine at Mount Sinai
  • Jeffrey Jhang; Icahn School of Medicine at Mount Sinai
  • Ania Wajnberg; Icahn School of Medicine at Mount Sinai
  • Florian Krammer; Icahn School of Medicine at Mount Sinai
  • Carlos Cordon-Cardo; Icahn School of Medicine at Mount Sinai
  • Sherlita Amler; Westchester County Department of Health
  • Marisa A Montecalvo; Westchester County Department of Health
  • Brad Hutton; New York State Department of Health
  • Jill Taylor; Wadsworth Center/New York State Department of Health
  • Kathleen A McDonough; Wadsworth Center/New York State Department of Health
Preprint in English | medRxiv | ID: ppmedrxiv-20150557
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
Passive transfer of antibodies from COVID-19 convalescent patients is being used as an experimental treatment for eligible patients with SARS-CoV-2 infections. The United States Food and Drug Administrations (FDA) guidelines for convalescent plasma recommends target antibody titers of 160. We evaluated SARS-CoV-2 neutralizing antibodies in sera from recovered COVID-19 patients using plaque reduction neutralization tests (PRNT) at low (PRNT50) and high (PRNT90) stringency thresholds. We found that neutralizing activity increased with time post symptom onset (PSO), reaching a peak at 31-35 days PSO. At this point, the number of sera having neutralizing titers of at least 160 was [~]93% (PRNT50) and [~]54% (PRNT90). Sera with high SARS-CoV-2 antibody levels (>960 ELISA titers) showed maximal activity, but not all high titer sera contained neutralizing antibody at FDA recommended levels, particularly at high stringency. These results underscore the value of serum characterization for neutralization activity.
License
cc_no
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies Language: English Year: 2020 Document type: Preprint
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies Language: English Year: 2020 Document type: Preprint